VSL #3
Natural health product licensed in Canada
- Licence holder
- Ferring Inc.
- NPN or DIN-HM
- 80042116
- Status
- Inactive licence
- Licence date
- 7 May 2013
- Revision date
- 15 March 2017
- Form
- Liquide oral, poudre
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Bifidobacterium animalis subsp. Lactis Source : Cellule entière | 2 % (p/p) | Not calculated |
| Bifidobacterium breve Source : Bifidobacterium breve - Cellule entière | 0.1 % (p/p) | Not calculated |
| Lactobacillus plantarum Source : Lactobacillus plantarum - Cellule entière | 0.1 % (p/p) | Not calculated |
| Lactobacillus acidophilus Source : Lactobacillus acidophilus - Cellule entière | 1 % (p/p) | Not calculated |
| Lactobacillus helveticus Source : En entier | 0.1 % (p/p) | Not calculated |
| Lactobacillus paracasei Source : Lactobacillus paracasei - Cellule entière | 8 % (p/p) | Not calculated |
| Streptococcus salivarius subsp. thermophilus Source : Streptococcus salivarius subsp. thermophilus-Cellule entière | 19 % (p/p) | Not calculated |
Non-medicinal ingredients
Amidon de maïs, Maltose, Dioxyde de silicium, Saveur
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | minimum: 2 Portion(s) ; maximum: 4 Portion(s) | minimum: 1 Tous les jours ; maximum: 2 Tous les jours |
Uses authorised in Canada
Text supplied in English because no French text is available.
Helps maintain the appropriate balance of beneficial bacteria in the bowel of pouchitis patients. VSL #3 is used to reduce the risk of relapse in pouchitis patients. VSL, in conjunction with mesalamine, helps reduce the Ulcerative Colitis Disease Activity Index (UCDAI) by half within 6 weeks in some non-hospitalized patients with mild to moderately active ulcerative colitis.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80042116
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2017. Photograph the packaging to check whether it has changed. Photograph the packaging